Sporicidal effect of amorolfine and other antimycotics used in the therapy of fungal nail infections

Mycoses
Hans P SeidlAnnemarie Polak

Abstract

Although topical antifungal therapies for treating onychomycosis are available, the cure rate is unsatisfactorily low with a simultaneously high risk of recurrence. One reason might be the formation of dormant fungal cells by the pathogen, known as spores, which can survive in the affected nail keratin, thereby evading the effect of antifungal drugs. In this in vitro study, the ability of amorolfine and four other antimycotics (ciclopirox, bifonazole, terbinafine and fluconazole) to kill microconidia of the dermatophyte Trichophyton rubrum, chlamydospores of the dermatophyte Epidermophyton floccosum and blastospores of the yeast Candida albicans was extensively studied as these fungi occur predominantly in onychomycosis. The effectiveness of all five antimycotics depended on the drug concentration and the incubation time: a concentration of 10-1000 times the minimum inhibitory concentration against growing hyphae cells is needed to exert a sporicidal action. Amorolfine and ciclopirox showed the same sporicidal efficacy and kinetics for all three varieties of spores. Both were more effective than fluconazole and bifonazole against microconidia and chlamydospores as well as slightly more potent against chlamydospores and blastosp...Continue Reading

References

Nov 1, 1977·Infection and Immunity·T Hashimoto, H J Blumenthal
Sep 1, 1992·Clinical and Experimental Dermatology·F PittrofG Klecak
Sep 1, 1992·Clinical and Experimental Dermatology·A M Polak
Jan 1, 1992·Dermatology : International Journal for Clinical and Investigative Dermatology·D Reinel
Jan 1, 1992·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·S H AljabreG S Shankland
Mar 1, 1989·Clinical and Experimental Dermatology·N Zaias, L Serrano
Nov 1, 1987·The Journal of Investigative Dermatology·J Zurita, R J Hay
Mar 1, 1993·Mycoses·A Polak
Dec 1, 1995·The British Journal of Dermatology·A RashidM D Richardson
Jan 1, 1996·Mycoses·C De VroeyC Raes-Wuytack
Jun 19, 1998·Journal of the American Academy of Dermatology·M R LingM R Young
Oct 30, 1998·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·C Seebacher
Oct 29, 2000·Journal of the American Academy of Dermatology·M Bohn, K T Kraemer
Apr 8, 2003·Pharmazie in unserer Zeit·Joachim Kresken
Mar 4, 2005·Mycoses·C FlagothierG E Piérard
Aug 27, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·M LechaUNKNOWN Taskforce on Onychomycosis Education
Oct 13, 2006·Journal of Medical Microbiology·S Amir Yazdanparast, Richard C Barton
Aug 27, 2010·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Matilde IorizzoAntonella Tosti
Apr 27, 2012·Expert Opinion on Pharmacotherapy·Aditya K Gupta, Fiona C Simpson
Oct 2, 2013·Clinics in Dermatology·Aditya K GuptaFiona C Simpson
Oct 26, 2013·Seminars in Cutaneous Medicine and Surgery·Richard K ScherBoni Elewski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.